Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 50microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 80microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 120microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 150microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 100microgram

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp dohme ltd  - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when viraferonpeg is to be used in combination with these medicines.adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.viraferonpeg in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.interferon monotherapy, including viraferonpeg, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when viraferonpeg is to be used in combination with ribavirin.paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when viraferonpeg is to be used in combination with ribavirin.

Israeli - Kiingereza - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

Israeli - Kiingereza - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - peginterferon alfa-2a - solution for injection - 270microgram/1ml